Viewing Study NCT02241551

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:53 PM
Ignite Modification Date: 2026-05-21 @ 9:12 PM
Study NCT ID: NCT02241551
Status: TERMINATED
Last Update Posted: 2018-07-26
First Post: 2014-08-29
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Sponsor: Nathan Bahary, MD
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Borderline Resectable Pancreatic Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Borderline View
None Resectable View
None Pancreatic View
None Cancer View
None Neoadjuvant View
None Chemotheraphy View
None Gemcitabine View
None Nab-Paclitaxel View
None mFOFIRINOX View
None Sterotatic Body Radiation Therapy View